NCT06220123View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

225

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Interventions

DRUG

SHR-2004

Investigational product arm: SHR-2004

DRUG

Enoxaparin Sodium Injection; Rivaroxaban Tablets

Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY

NCT06220123 - A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | Biotech Hunter | Biotech Hunter